Clinical Edge Journal Scan

MRI helpful for predicting uterine fibroids shrinkage after GnRH-agonist treatment


 

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802 .

Recommended Reading

OAE improves outcomes in women with persistent symptoms after UAE for uterine fibroids
MDedge ObGyn
Distinct clinical characteristics and typical morphology distinguishes HLRCC and sporadic uterine leiomyomas
MDedge ObGyn
TVUS + SE presents a specific and sensitive technique for differential diagnosis of uterine fibroids and adenomyosis
MDedge ObGyn
The influence of uterine fibroids on fertility in women planning to become pregnant
MDedge ObGyn
Clinical Edge Journal Scan Commentary: Uterine Fibroids October 2021
MDedge ObGyn
T2 relaxation time predicts effectiveness of MRgHIFU treatment of uterine fibroids
MDedge ObGyn
Single-port laparoscopy myomectomy feasible for treatment of uterine fibroids
MDedge ObGyn
Aging may impair restoration of endometrial blood flow after laparoscopic myomectomy
MDedge ObGyn
Single-layer sutured laparoscopic myomectomy appears safe for subsequent pregnancies
MDedge ObGyn
Uterine fibroids: Nonresponders to elagolix+add-back therapy may still have a clinically meaningful response
MDedge ObGyn